Evidence status: each field states its source quality, applicability, and review date. Research pending, information not established, and vendor documentation pending remain distinct outcomes.
Product overview
Start with the essentials
Authorized purpose: Non-contrast head CT triage for suspected intracranial hemorrhage in adults aged 22 and older.
Overview status: Source-reviewed overview
What does this software do?Authorized purpose: Non-contrast head CT triage for suspected intracranial hemorrhage in adults aged 22 and older.
Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Brain/Head Input: DICOM-compliant non-contrast head CT images from adults aged 22 and older.
Who uses it?Intended users: Trained radiologists.
What does the software produce?Output: A binary suspected-ICH present/not-present finding returned to a third-party worklist to alert radiologists; it does not provide ICH subtype classification and has no user interface of its own.
What is its most important limitation?Key limitation: Not a diagnostic device; patients under 22 are excluded; unflagged or unreviewed cases remain in standard processing; the original full images require radiologist review.
Clinical takeaway
Clinical role: Non-contrast head CT triage for suspected intracranial hemorrhage in adults aged 22 and older.
Evidence takeaway
Evidence from the reviewed source record: FDA retrospective performance study: 294 cases from three U.S. institutions, ground truth by three ABR-certified trained neuroradiologists with an experience-based tie breaker. The study included 63.9% ICH and 36.1% non-ICH cases, with two institutions independent of development data. Sensitivity was 0.867 (95% CI 0.811-0.908), specificity 0.887 (0.812-0.934), and ROC AUC 0.926. The FDA summary states clinical tests were not conducted; this was retrospective performance testing/non-clinical evidence.
Clinical details
What this tool is for
Start with the authorized purpose, then verify how it fits your service line and reading workflow.
Exact purpose
Non-contrast head CT triage for suspected intracranial hemorrhage in adults aged 22 and older.
A binary suspected-ICH present/not-present finding returned to a third-party worklist to alert radiologists; it does not provide ICH subtype classification and has no user interface of its own.
Not a diagnostic device; patients under 22 are excluded; unflagged or unreviewed cases remain in standard processing; the original full images require radiologist review.
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
Use these fields to structure a vendor demo, security review, and implementation estimate.
Integration
Software-only device integrated with a third-party worklist on standard off-the-shelf or virtual server hardware; it receives DICOM analysis requests/images and returns the suspected-ICH finding. Exact local interfaces and deployment topology are not established.
Deployment category preserved from the prior exact-submission review; hosting region, data flow, and current commercial configuration still require vendor confirmation.
ACR AI Central provides an exact-submission model card for Scaida BrainCT-ICH (v1.0); FDA labeling remains controlling for clinical use, limitations, and performance.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
FDA retrospective performance study: 294 cases from three U.S. institutions, ground truth by three ABR-certified trained neuroradiologists with an experience-based tie breaker. The study included 63.9% ICH and 36.1% non-ICH cases, with two institutions independent of development data. Sensitivity was 0.867 (95% CI 0.811-0.908), specificity 0.887 (0.812-0.934), and ROC AUC 0.926. The FDA summary states clinical tests were not conducted; this was retrospective performance testing/non-clinical evidence.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
Scaida BrainCT-ICH (v1.0) regulatory performance study summary
DesignStand-Alone Performance
PopulationAdult
Scopeexact submission
Tested versionExact product version not reported; regulatory study summarized for FDA submission K250694
Samplen=294
Sites3
IndependenceIndependence not established
K250694
ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.
These are common procurement questions; unknown values remain visible until a source supports them.
Pricing and total cost
Vendor documentation pending
Vendor confirmation
Exact FDA submission
Checked 2026-09-08
No public price or quote for the exact K250694 configuration was established in this review.
Reimbursement and coding
Not established in reviewed sources
Reviewed sources checked
Exact FDA submission
Checked 2026-09-08
No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.
Safety and lifecycle
Postmarket record
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K250694. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
Verify security and privacy controls: Exact-release security controls, data retention, hosting boundaries, and scoped assurance documentation require vendor confirmation.
Verify training: Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.
Verify pricing and total cost: No public price or quote for the exact K250694 configuration was established in this review.
Verify reimbursement and coding relevance: No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.
Verify local validation and lifecycle monitoring: Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-19Last searched
26Fields reviewed
9Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall
Sources & history
How this profile was documented
Open the ledger for source dates, scope, and research-record updates.
View source ledger and history7 sources - 3 history items
Case-level prioritization and passive notification for adult non-contrast head CT studies with features suggestive of acute intracranial hemorrhage (ICH); not a stand-alone...
Study-level triage and prioritization notification for suspected mass effect on non-contrast brain CT in patients aged 22 years and older; not a stand-alone decision or rule-out...
Notification-only triage of adult non-contrast head CT for suspected intracranial hemorrhage and large-vessel occlusion, with parallel communication to trained clinicians during...
Modality
CT/CTA
Anatomy
Brain and intracranial vessels: intracranial hemorrhage and LVO involving ICA, MCA-M1, and MCA-M2